Stock Rating Upgrade
In the last week the Value Trend Rating for Fate Therapeutics Inc (NASDAQ: FATE) improved from C to B reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
On 4/26/24, Fate Therapeutics Inc (NASDAQ: FATE) stock declined modestly by -1.8%, closing at $3.80. NORMAL trading volume accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -24.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, FATE is expected to be Value Creation neutral.
Fate Therapeutics has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Fate Therapeutics has a poor Appreciation Score of 28 but a very high Power Rating of 98, producing the Positive Value Trend Rating.
Be the first to comment